CA1063934A - Microsealed pharmaceutical delivery device - Google Patents
Microsealed pharmaceutical delivery deviceInfo
- Publication number
- CA1063934A CA1063934A CA238,197A CA238197A CA1063934A CA 1063934 A CA1063934 A CA 1063934A CA 238197 A CA238197 A CA 238197A CA 1063934 A CA1063934 A CA 1063934A
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical
- biologically acceptable
- silicone polymer
- microsealed
- delivery device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229920000642 polymer Polymers 0.000 claims abstract description 84
- 239000011159 matrix material Substances 0.000 claims abstract description 67
- 229920005573 silicon-containing polymer Polymers 0.000 claims abstract description 59
- 239000002904 solvent Substances 0.000 claims abstract description 56
- 239000007788 liquid Substances 0.000 claims abstract description 15
- 238000011065 in-situ storage Methods 0.000 claims abstract description 10
- 238000004132 cross linking Methods 0.000 claims abstract description 8
- 239000000839 emulsion Substances 0.000 claims abstract description 5
- 238000005192 partition Methods 0.000 claims abstract description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000002202 Polyethylene glycol Substances 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 229940012028 ethynodiol diacetate Drugs 0.000 claims description 12
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 claims description 12
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 9
- 229920001971 elastomer Polymers 0.000 claims description 9
- 229920002554 vinyl polymer Polymers 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 8
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 239000003431 cross linking reagent Substances 0.000 claims description 5
- 239000000806 elastomer Substances 0.000 claims description 5
- 239000004417 polycarbonate Substances 0.000 claims description 4
- 229920000515 polycarbonate Polymers 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 3
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 claims description 3
- 229960001390 mestranol Drugs 0.000 claims description 3
- 239000000186 progesterone Substances 0.000 claims description 3
- 229960003387 progesterone Drugs 0.000 claims description 3
- 239000000583 progesterone congener Substances 0.000 claims description 3
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- 229960002568 ethinylestradiol Drugs 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- 229920002529 medical grade silicone Polymers 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 3
- JQZRVMZHTADUSY-UHFFFAOYSA-L di(octanoyloxy)tin Chemical compound [Sn+2].CCCCCCCC([O-])=O.CCCCCCCC([O-])=O JQZRVMZHTADUSY-UHFFFAOYSA-L 0.000 claims 2
- JBFHTYHTHYHCDJ-UHFFFAOYSA-N gamma-caprolactone Chemical compound CCC1CCC(=O)O1 JBFHTYHTHYHCDJ-UHFFFAOYSA-N 0.000 claims 2
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 claims 1
- 239000003470 adrenal cortex hormone Substances 0.000 claims 1
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 claims 1
- 229960003654 desoxycortone Drugs 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 230000003455 independent Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- -1 polyethylene Polymers 0.000 description 14
- 229920000260 silastic Polymers 0.000 description 9
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 7
- 239000005977 Ethylene Substances 0.000 description 7
- 229920001577 copolymer Polymers 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 229920002379 silicone rubber Polymers 0.000 description 7
- 239000000203 mixture Substances 0.000 description 5
- 239000004945 silicone rubber Substances 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 239000005060 rubber Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 229940000425 combination drug Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229920005597 polymer membrane Polymers 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102100038916 Caspase-5 Human genes 0.000 description 2
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 2
- 101100112336 Homo sapiens CASP5 gene Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 101100273286 Mus musculus Casp4 gene Proteins 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229960004486 desoxycorticosterone acetate Drugs 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- PLYIPBIZXSTXCW-UHFFFAOYSA-N octanoic acid;tin Chemical compound [Sn].CCCCCCCC(O)=O PLYIPBIZXSTXCW-UHFFFAOYSA-N 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004709 Chlorinated polyethylene Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 239000004944 Liquid Silicone Rubber Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 241001163743 Perlodes Species 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- FFIAPLNALYDYQK-UHFFFAOYSA-L barium(2+);[2,3,4-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methyl phosphate Chemical compound [Ba+2].OCC1OC(O)(COP([O-])([O-])=O)C(O)C1O FFIAPLNALYDYQK-UHFFFAOYSA-L 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 150000004862 dioxolanes Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920005558 epichlorohydrin rubber Polymers 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940074076 glycerol formal Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- SXQFCVDSOLSHOQ-UHFFFAOYSA-N lactamide Chemical compound CC(O)C(N)=O SXQFCVDSOLSHOQ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000004957 nitroimidazoles Chemical class 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940095050 propylene Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000007811 spectroscopic assay Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/2036—Silicones; Polysiloxanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US05/517,454 US3946106A (en) | 1974-10-24 | 1974-10-24 | Microsealed pharmaceutical delivery device |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1063934A true CA1063934A (en) | 1979-10-09 |
Family
ID=24059857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA238,197A Expired CA1063934A (en) | 1974-10-24 | 1975-10-23 | Microsealed pharmaceutical delivery device |
Country Status (15)
Country | Link |
---|---|
US (1) | US3946106A (en, 2012) |
JP (1) | JPS6059202B2 (en, 2012) |
AR (1) | AR206946A1 (en, 2012) |
AT (1) | AT347594B (en, 2012) |
AU (1) | AU499873B2 (en, 2012) |
BE (1) | BE834785A (en, 2012) |
CA (1) | CA1063934A (en, 2012) |
DE (1) | DE2547378A1 (en, 2012) |
DK (1) | DK141008B (en, 2012) |
ES (1) | ES442017A1 (en, 2012) |
FR (1) | FR2289207A1 (en, 2012) |
GB (1) | GB1522846A (en, 2012) |
IE (1) | IE42056B1 (en, 2012) |
NL (1) | NL190102C (en, 2012) |
ZA (1) | ZA756352B (en, 2012) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3992518A (en) * | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
US4053580A (en) * | 1975-01-01 | 1977-10-11 | G. D. Searle & Co. | Microsealed pharmaceutical delivery device |
JPS52151504A (en) * | 1976-06-11 | 1977-12-16 | Hitachi Ltd | Alarm sending system |
US4145408A (en) * | 1976-08-16 | 1979-03-20 | The Procter & Gamble Company | Controlled release article |
HU174057B (hu) * | 1976-09-17 | 1979-10-28 | Richter Gedeon Vegyeszet | Sostav dlja pokrytij obespechivajuhhij uregulirovannuju otdachy aktivnogo vehhestva biologicheski aktivnykh preparatov i sposob poluchenija takikh preparatov s uregulirovannoj otdachej aktivnogo vehhestva |
US4191741A (en) * | 1978-09-22 | 1980-03-04 | Eli Lilly And Company | Removable drug implant |
DE2902414A1 (de) * | 1979-01-23 | 1980-08-07 | Hoechst Ag | Depotkoerper auf basis silicon- kautschuk sowie verfahren zu seiner herstellung |
DE2914463A1 (de) * | 1979-04-10 | 1980-10-23 | Hoechst Ag | Medizinische geraete fuer parenterale fluessigkeiten |
EP0081370A1 (en) * | 1981-12-07 | 1983-06-15 | Syntex (U.S.A.) Inc. | Disposable intravaginal contraceptive devices releasing 1-substituted imidazoles |
US4469671A (en) * | 1983-02-22 | 1984-09-04 | Eli Lilly And Company | Contraceptive device |
GB8319766D0 (en) * | 1983-07-22 | 1983-08-24 | Graham N B | Controlled release device |
US4563184A (en) * | 1983-10-17 | 1986-01-07 | Bernard Korol | Synthetic resin wound dressing and method of treatment using same |
US5225196A (en) * | 1983-11-14 | 1993-07-06 | Columbia Laboratories, Inc. | Bioadhesive compositions and methods of treatment therewith |
FR2570602B1 (fr) * | 1984-09-21 | 1986-11-28 | Cird | Vehicule pharmaceutique pour substances actives se presentant sous forme d'un gel anhydre |
US4927687A (en) * | 1984-10-01 | 1990-05-22 | Biotek, Inc. | Sustained release transdermal drug delivery composition |
EP0184910B1 (en) * | 1984-11-15 | 1992-09-30 | Hercon Laboratories Corporation | Device for controlled release drug delivery |
US4806341A (en) * | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
US4673565A (en) * | 1985-05-03 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Pharmaceutical compositions containing hollow fine tubular drug delivery systems |
US4720384A (en) * | 1985-05-03 | 1988-01-19 | E. I. Du Pont De Nemours And Company | Manufacture of hollow fine tubular drug delivery systems |
US4690683A (en) * | 1985-07-02 | 1987-09-01 | Rutgers, The State University Of New Jersey | Transdermal varapamil delivery device |
US5266329A (en) * | 1985-10-31 | 1993-11-30 | Kv Pharmaceutical Company | Vaginal delivery system |
US4959217A (en) * | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
US5560922A (en) * | 1986-05-30 | 1996-10-01 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process |
US5422118A (en) * | 1986-11-07 | 1995-06-06 | Pure Pac, Inc. | Transdermal administration of amines with minimal irritation and high transdermal flux rate |
US4906475A (en) * | 1988-02-16 | 1990-03-06 | Paco Pharmaceutical Services | Estradiol transdermal delivery system |
US5945125A (en) * | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
FR2766088B1 (fr) * | 1997-07-17 | 2001-01-05 | Dow Corning Sa | Dispositifs a liberation controlee d'un agent pharmaceutique, leur fabrication par co-extrusion et article intermediaire |
US6733767B2 (en) * | 1998-03-19 | 2004-05-11 | Merck & Co., Inc. | Liquid polymeric compositions for controlled release of bioactive substances |
HU229085B1 (en) | 1999-07-02 | 2013-07-29 | Lohmann Therapie Syst Lts | Microreservoir system on the basis of polysiloxanes and ambiphilic solvents |
CA2503193A1 (en) * | 2002-10-22 | 2004-05-06 | The Biomerix Corporation | Method and system for intravesicular delivery of therapeutic agents |
US20050043585A1 (en) * | 2003-01-03 | 2005-02-24 | Arindam Datta | Reticulated elastomeric matrices, their manufacture and use in implantable devices |
EP1438942A1 (en) * | 2003-01-17 | 2004-07-21 | Schering Oy | An otorhinological drug delivery device |
DK1613297T3 (da) * | 2003-04-14 | 2007-09-24 | Lohmann Therapie Syst Lts | Terapeutisk plaster med polysiloxanmatrix indeholdende capsaicin |
US7803395B2 (en) | 2003-05-15 | 2010-09-28 | Biomerix Corporation | Reticulated elastomeric matrices, their manufacture and use in implantable devices |
US7763077B2 (en) | 2003-12-24 | 2010-07-27 | Biomerix Corporation | Repair of spinal annular defects and annulo-nucleoplasty regeneration |
US20070190108A1 (en) * | 2004-05-17 | 2007-08-16 | Arindam Datta | High performance reticulated elastomeric matrix preparation, properties, reinforcement, and use in surgical devices, tissue augmentation and/or tissue repair |
US20060116714A1 (en) * | 2004-11-26 | 2006-06-01 | Ivan Sepetka | Coupling and release devices and methods for their assembly and use |
US20080281350A1 (en) * | 2006-12-13 | 2008-11-13 | Biomerix Corporation | Aneurysm Occlusion Devices |
WO2024189206A1 (en) | 2023-03-15 | 2024-09-19 | Lts Lohmann Therapie-Systeme Ag | Hexagonal self-adhesive layer structure |
WO2024189213A1 (en) | 2023-03-15 | 2024-09-19 | Lts Lohmann Therapie-Systeme Ag | Medical patch comprising skin irritating active agent |
WO2024189202A1 (en) | 2023-03-15 | 2024-09-19 | Lts Lohmann Therapie-Systeme Ag | Medical patch comprising capsaicin |
WO2024223146A1 (en) | 2023-04-28 | 2024-10-31 | Lts Lohmann Therapie-Systeme Ag | Pentagonal self-adhesive layer structure |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3279996A (en) * | 1962-08-28 | 1966-10-18 | Jr David M Long | Polysiloxane carrier for controlled release of drugs and other agents |
US3416530A (en) * | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
US3545439A (en) * | 1968-01-04 | 1970-12-08 | Upjohn Co | Medicated devices and methods |
US3518340A (en) * | 1968-04-15 | 1970-06-30 | Dow Corning | Method of forming silicone rubber drug carriers |
US3845761A (en) * | 1970-06-02 | 1974-11-05 | Alza Corp | Intrauterine contraceptive anti-fertility device for the management of reproduction |
US3832252A (en) * | 1970-09-29 | 1974-08-27 | T Higuchi | Method of making a drug-delivery device |
US3710795A (en) * | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
AU454482B2 (en) * | 1970-11-05 | 1974-10-15 | Alza Corporation | Drug-delivery system |
US3797485A (en) * | 1971-03-26 | 1974-03-19 | Alza Corp | Novel drug delivery device for administering drug into blood circulation in blood vessel |
US3828777A (en) * | 1971-11-08 | 1974-08-13 | Alza Corp | Microporous ocular device |
US3832458A (en) * | 1971-12-06 | 1974-08-27 | River C Foundation | Hydrophilic silicone composition and method |
-
1974
- 1974-10-24 US US05/517,454 patent/US3946106A/en not_active Expired - Lifetime
-
1975
- 1975-01-01 AR AR260899A patent/AR206946A1/es active
- 1975-10-07 ZA ZA756352A patent/ZA756352B/xx unknown
- 1975-10-23 AU AU85974/75A patent/AU499873B2/en not_active Expired
- 1975-10-23 IE IE2310/75A patent/IE42056B1/en unknown
- 1975-10-23 DE DE19752547378 patent/DE2547378A1/de active Granted
- 1975-10-23 NL NLAANVRAGE7512430,A patent/NL190102C/xx not_active IP Right Cessation
- 1975-10-23 JP JP50127859A patent/JPS6059202B2/ja not_active Expired
- 1975-10-23 DK DK478275AA patent/DK141008B/da not_active IP Right Cessation
- 1975-10-23 FR FR7532526A patent/FR2289207A1/fr active Granted
- 1975-10-23 BE BE161172A patent/BE834785A/xx not_active IP Right Cessation
- 1975-10-23 GB GB43554/75A patent/GB1522846A/en not_active Expired
- 1975-10-23 ES ES442017A patent/ES442017A1/es not_active Expired
- 1975-10-23 CA CA238,197A patent/CA1063934A/en not_active Expired
- 1975-10-24 AT AT812775A patent/AT347594B/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JPS5167719A (en, 2012) | 1976-06-11 |
DE2547378C2 (en, 2012) | 1990-03-15 |
ZA756352B (en) | 1977-05-25 |
GB1522846A (en) | 1978-08-31 |
NL190102B (nl) | 1993-06-01 |
IE42056B1 (en) | 1980-05-21 |
FR2289207B1 (en, 2012) | 1979-09-14 |
DK141008B (da) | 1979-12-24 |
DK141008C (en, 2012) | 1980-06-09 |
AT347594B (de) | 1979-01-10 |
AU499873B2 (en) | 1979-05-03 |
DK478275A (en, 2012) | 1976-04-25 |
JPS6059202B2 (ja) | 1985-12-24 |
DE2547378A1 (de) | 1976-04-29 |
ATA812775A (de) | 1978-05-15 |
IE42056L (en) | 1976-04-24 |
ES442017A1 (es) | 1977-06-16 |
BE834785A (fr) | 1976-04-23 |
FR2289207A1 (fr) | 1976-05-28 |
AR206946A1 (es) | 1976-08-31 |
NL7512430A (nl) | 1976-04-27 |
NL190102C (nl) | 1993-11-01 |
AU8597475A (en) | 1977-04-28 |
US3946106A (en) | 1976-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1063934A (en) | Microsealed pharmaceutical delivery device | |
US3992518A (en) | Method for making a microsealed delivery device | |
US4053580A (en) | Microsealed pharmaceutical delivery device | |
US3845761A (en) | Intrauterine contraceptive anti-fertility device for the management of reproduction | |
AU760302B2 (en) | Drug delivery device, especially for the delivery of progestins and estrogens | |
US4014335A (en) | Ocular drug delivery device | |
US3961628A (en) | Ocular drug dispensing system | |
ES2360806T3 (es) | Composiciones de liberación prolongada que contienen moduladores de receptores de progesterona. | |
CA2233753C (en) | Drug delivery system for two or more active substances | |
KR100392435B1 (ko) | 성스테로이드를함유하는경피치료시스템 | |
KR0137463B1 (ko) | 게스토덴을 함유하는 경피 투여용 제제 | |
US4188951A (en) | Intrauterine system embracing selected copolymeric membranes for administering beneficial agent | |
JPS584574B2 (ja) | 固体のゼロオ−ダ−放出装置 | |
AU769229B2 (en) | Drug delivery device, especially for the delivery of androgens | |
Wright et al. | Drug Delivery Systems Based on Diffusion and Osmosis | |
JP2000514065A (ja) | ドラッグデリバリーディバイスとその製造法 | |
Nash et al. | Patent: Intravaginal ring | |
Gröning et al. | P249 magnetic dosage forms with controlled gastric residence time | |
Moo-Young et al. | Patent: Male contraceptive implant | |
Harris et al. | A Study of the in Vitro Release Profile of a New Prostaglandin E2 Delivery System for Local Administration in Obstetrics | |
Vitková et al. | P252 influence of exogenous factors on the formulation of heptacaine containing drug forms | |
SE425212B (sv) | Forfarande for framstellning av en anordning ur vilken ett deri inneslutet lekemedel kan frigoras under inverkan av kroppsvetskor | |
MXPA98002799A (en) | System of delivery of medication for two or massubstancias acti |